ANI Revises Its Expectations Up Following Record Revenues

Analysts Conservative About Company Future Despite Banner Performance

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.

Bar chart with ascending columns ridden by a man on a red bull
ANI has raised its revenue guidance by approximately 26% • Source: Shutterstock

ANI Pharmaceuticals, Inc. has revised up its full-year guidance for 2023 following a record quarter, as the firm’s pivotal Cortrophin gel (repository corticotropin injection) 80 U/ml launch and scale-up of its generics business – boosted by competitor supply disruption during Q1 – continue to propel the firm forward.

The company ultimately raised its annual net revenue guidance to $385m-$410m, from a previous estimate of $360m-$385m. It also increased...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business